| scholarly article | Q13442814 |
| P50 | author | David E. Kleiner | Q41449492 |
| P2093 | author name string | Yoon Park | |
| T Jake Liang | |||
| Theo Heller | |||
| Marc G Ghany | |||
| Jay H Hoofnagle | |||
| Ponni Perumalswami | |||
| Glen Lutchman | |||
| Brian Borg | |||
| P2860 | cites work | Cloning of adiponectin receptors that mediate antidiabetic metabolic effects | Q24304889 |
| Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis | Q27477968 | ||
| Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets | Q27481061 | ||
| Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| Pathogenesis, natural history, treatment, and prevention of hepatitis C. | Q33841882 | ||
| Chronic hepatitis C and superimposed nonalcoholic fatty liver disease | Q34308953 | ||
| The spectrum of liver disease in the general population: lesson from the Dionysos study. | Q34420591 | ||
| AGA technical review on nonalcoholic fatty liver disease | Q34982453 | ||
| Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. | Q35598407 | ||
| Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial | Q42008293 | ||
| Hepatitis C virus core protein induces hepatic steatosis in transgenic mice | Q42983905 | ||
| Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. | Q42999424 | ||
| Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity | Q43031928 | ||
| Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial | Q43034904 | ||
| Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group | Q43037170 | ||
| Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response | Q43040638 | ||
| Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients | Q43041131 | ||
| Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. | Q43659671 | ||
| NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome | Q43875846 | ||
| Apolipoprotein synthesis in nonalcoholic steatohepatitis | Q43933950 | ||
| Progression of fibrosis in chronic hepatitis C. | Q44269259 | ||
| Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. | Q44421358 | ||
| The long-term pathological evolution of chronic hepatitis C. | Q44765507 | ||
| The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis | Q46858579 | ||
| Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation | Q61895904 | ||
| The pathology of hepatitis C | Q68079260 | ||
| Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group | Q70542346 | ||
| Non-alcoholic fatty liver disease | Q74052826 | ||
| Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis | Q74645276 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | steatosis | Q1365091 |
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 780-787 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. | |
| P478 | volume | 43 |
| Q36172470 | A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease |
| Q42984502 | Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection |
| Q39932638 | Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C. |
| Q35987307 | Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi |
| Q37217299 | Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial |
| Q37523542 | Fibrosis in Chronic Hepatitis C: Correlation between Immunohistochemically-Assessed Virus Load with Steatosis and Cellular Iron Content |
| Q43034053 | Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis |
| Q45126678 | Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. |
| Q36174863 | Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis |
| Q36248186 | IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. |
| Q36490255 | Impact of obesity on treatment of chronic hepatitis C. |
| Q53804213 | Impact of steatosis on insulin secretion in chronic hepatitis C patients. |
| Q42244227 | Lipid droplet binding of hepatitis C virus core protein genotype 3. |
| Q38056643 | Lipids and HCV. |
| Q37924816 | Metabolic alterations and chronic hepatitis C: treatment strategies |
| Q43031835 | Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection |
| Q26745576 | NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations |
| Q50934392 | Natural History of Hepatitis C. |
| Q83489556 | Non-alcoholic fatty liver disease and antiviral therapy in hepatitis C |
| Q27489097 | Pathological evolution of hepatitis C virus-“Healthy carriers” |
| Q48591916 | Quantification of portal-bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C. |
| Q37944951 | Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis |
| Q34385138 | Role of simple biomarkers in predicting fibrosis progression in HCV infection |
| Q42981392 | Serum level of adiponectin correlated with gender and genotype in patients with chronic hepatitis C. |
| Q42987385 | Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis |
| Q34207037 | Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression |
| Q35142681 | Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial |
| Q81415779 | [Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors] |
Search more.